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AbstrAct:
Adenoviruses are the most commonly used vectors for gene therapy. Despite 
the  promising  safety  profile  demonstrated  in  clinical  trials,  the  efficacy  of  using 
adenoviruses for gene therapy is poor. A major hurdle to adenoviral-mediated gene 
therapy is the innate immune system. Cell-mediated recognition of viruses via 
capsid components or nucleic acids has received significant attention, principally 
thought to be regulated by the toll-like receptors (TLRs). Antiviral innate immune 
responses are initiated by the infected cell, which activates the interferon (IFN) 
response to block viral replication, while simultaneously releasing chemokines 
to attract neutrophils, mononuclear- and natural killer-cells. While the IFN and 
cellular recruitment pathways are activated and regulated independently of each 
other, both are required to overcome immune escape mechanisms by adenoviruses. 
Recent work has shown that the generation of adenoviral vectors lacking 
specific  transcriptionally-active  regions  decreases  immune  system  activation 
and increases the chance for immune escape. In this review, we elucidate how 
adenoviral  vector  modifications  alter  the  IFN  and  innate  inflammatory  pathway 
response and propose future targets with clinically-translational relevance.
IntroductIon
Adenoviruses are a continuously expanding class of 
at least 51 immunologically distinct serotypes [1] classified 
into 6 species (A-F) based on their hemagglutination 
properties, oncogenic potential, genotyping and 
phylogenetic analyses [2]. A small number of viral particles 
are sufficient to induce symptoms that will be determined 
by the adenovirus type and the inflammatory mediators 
[3]. In immunocompetent hosts, adenoviruses cause mild 
ocular, respiratory and gastrointestinal tract diseases. 
Thus, the safety profile for adenoviral administration into 
animals has been one of the reasons for their widespread 
use as gene therapy vectors. Although local injections 
have proven to be safe in clinical trials, intravascular 
delivery has been associated with one reported fatality 
[4]. An acute inflammatory response to the adenoviral 
vector was later determined to be the cause of the fatality. 
Therefore, investigating the complex interplay between 
adenoviruses and the immune system is of paramount 
importance for future safe and effective gene therapy.
AdenovIrus bIology
The adenovirus is a dsDNA non-enveloped virus of 
70-90nm in size (Figure 1A). Its core, a 36kB double-
stranded  linear  DNA  is  packed  within  the  icosahedral 
capsid [5]. The viral genome encodes several early (E1A, 
E1B, E2, E3 and E4) and late (L1-5) transcriptional units 
(Figure 1B) that give rise to multiple mRNAs and proteins 
via differential processing [6]. The capsid proteins are 
the primary antigens that define the various serotypes. 
Hexon- and penton-subunits form the icosahedral ‘shell’, 
while fiber protrusions help the virus to anchor to the cell 
surface.
Adenoviral transduction
Initial attachment of virion particles is mediated 
by  the  interaction  of  the  fiber  knob  domain  with  the Oncotarget 2011; 2:  113 - 121 114 www.impactjournals.com/oncotarget
Coxsackie-Adenovirus Receptor (CAR) for all groups 
beside  B,  which  uses  CD46  [7,  8].  Internalization, 
via clathrin-dependent endocytosis, is mediated by a 
secondary interaction of the RGD motif on the penton base 
with αv integrins on the cell surface [9]. While endosomal 
escape is known to be dependent on the acidity of the 
microenvironment, the molecular steps that govern viral 
escape remain to be elucidated. Once in the cytoplasm, 
virion trafficking is guided by dynein along microtubules, 
which  docks  to  the  nuclear  pore  complex  where  viral 
DNA enters the nucleus [10, 11]. All of the steps including 
viral attachment and intracellular escape, as well as DNA 
transcription, take only 10 minutes [12]. 
the InterleukIn-1/InflAmmAtory 
PAthwAy
The complexity of the innate immune response is 
matched only by the diversity of experimental designs 
that are used to investigate it. Different routes of delivery, 
conditions, time points and targets make this complicated 
system even more difficult to understand, which includes 
high levels of redundancy and cell-type specificity [12, 
13].  Thus,  understanding  how  all  of  these  seemingly 
different responses and measurable variables are related 
is required.
In this review, we offer a more structured approach 
to understanding the innate immune response as a result 
of  adenoviral  entry  by  dissecting  the  major  pathways 
involved. Of the many independent receptors in innate 
immunity, two stand out: the interferon α receptor (IFN-
AR) and interleukin-1 receptor (IL-1R) The downstream 
effectors of IFN-AR and IL-1R diverge to block viral 
replication using different signal transduction pathways. 
While  the  IFN  response  acts  in  an  autocrine/paracrine 
fashion to contain and destroy the virus from within the 
cell, the interleukin pathway recruits a pro-inflammatory 
infiltrate to eliminate the pathogen. 
The  quick  nature  of  the  inflammatory  responses 
suggests that an early recognition of the virus activates 
an immature form of IL-1 which resides in the cytosol. 
But the maximum inflammatory response relies on a fully-
functioning IL-1R [12, 14] and a number of protein kinases 
induced upon infection (Figure 1). These protein kinases, 
JNK,  ERK1/2  and  p38  MAPK,  are  also  downstream 
effectors of non-specific stress response pathways [15]. 
The earliest sensor to be activated upon viral 
infection appears to be triggered by the adenoviral fiber 
binding  with  the  CAR  [16].  While  the  downstream 
signaling of CAR has yet to be elucidated, recent work 
has shown that CAR promotes the clustering of junctional 
adhesion molecule-like protein (JAML) and activation of 
phosphoinositide  3-kinase  (P13K)  [17].  Irrespective  of 
the possible effectors involved [18], adenovirus binding 
to CAR induces downstream signaling of ERK1/2, JNK 
and MAPK, followed by NF-κB activation (Figure 2) and 
the up-regulation of chemokines. 
Current dogma supports the hypothesis that the 
earliest event inducing innate immunity is the interaction 
of the RGD motif with αv integrins, especially B3 [12]. 
Furthermore, the downstream signaling of αv integrins 
induces  NF-κB  activation  and  subsequently  increases 
IL-1  expression,  which  has  been  reviewed  elsewhere   
[19]. Importantly, the intensity of this response depends 
on endosomal viral escape and the presence of foreign 
figure 1: Adenovirus structure and transcription regions. 
A) Adenovirus capsid is composed of three major and four minor 
proteins. The three major proteins plus protein IX form the outer 
surface.  Reproduced  with  permission  [5]  B) The double stranded 
DNA adenoviral linear genome is covalently linked at its ends to 
terminal proteins via inverted terminal repeats (ITRs). The first viral 
transcription unit to be expressed is E1A that activates the other early 
adenovirus transcripts (E1B, E2, E3 and E4). Late gene transcription 
(L1-L5) is activated after the onset of DNA replication and is under 
the  control  of  major  late  promoter  (MLP).  Arrows  indicate  the 
direction of transcription.Oncotarget 2011; 2:  113 - 121 115 www.impactjournals.com/oncotarget
DNA, since empty capsids do not induce transcription of 
chemokines [13]. 
Once  internalized  within  host  cells,  adenoviral 
dsDNA can be sensed within the endosome via several 
TLRs [20] such as TLR9; in the cytosol by DNA-
dependent activator of IFN-regulatory factors (DAI) 
and/or  nucleotide  oligomerization  domain  (NOD)-like 
receptors (NLRs). Thus, the context of the immune 
response will depend on which of the pathways become 
activated.  Downstream  effectors  of  activated  TLR9 
diverge to activate both IFN- and inflammatory-responses. 
Accordingly, DAI relies on the IκB kinases, TBK1/IKKi, 
to induce the IFN response [21]. In contrast, NLRs bind 
with apoptosis speck protein (ASC) and caspases to form 
the  ‘inflammasome’  [22],  which  cleaves  the  immature 
forms  of  pro-IL-1  and  pro-IL-18  into  their  mature 
and  active  forms  [23].  Subsequently,  IL-1R  activation 
leads to activation of NF-κB followed by the release of 
various chemokines (Table 1) [12, 16, 18, 24-29]. The 
broad effects of chemokines induced during adenoviral 
delivery  have  to  be  considered  when  designing  gene 
therapy vectors. The resulting immune derangements, 
ranging from immunosuppression to autoimmunity, play 
a significant role in pathogenesis. The ability to decrease 
the level of inflammation [30] or enhance and modulate 
the immune response [31] with adenoviral vectors will 
increase the potential for immunotherapeutic success. 
Figure 2: Inflammatory response to adenovirus infection. CAR or integrin binding to adenovirus triggers PI3K and MAPK kinases. 
NLRs activate IL-1/18 which act via IL-1R to induce IKK kinases, which are also induced by recognition of viral DNA in endosomes. After 
kinases release NF from NF-κB, it transfers to the nucleus to induce chemokine transcription.
Chemokine Triggered pathway  Reference
IL-1 The 'endogenous pyrogen', induces production of all the other cytokines 12
IL-18   Enhances T and NK cell maturation, cytokine production and cytotoxicity  25
IL-8  Polymorphonuclear leukocyte chemotaxis and activation 26
GRO-α,γ  Structurally and functionally similar to IL-8 16
IL-6 Secreted by monocytes and macrophages during adenovirus infection 24
CXCL1  Induces neutrophil chemotaxis and respiratory burst activity 27
MCP-1  Monocyte and T-lymphocyte chemotactic factor 28
RANTES  Chemotactic factor for NK cells 29
TNF-α  Triggers apoptosis or necrosis in infected cells 18
Table 1: Triggered innate inflammatory pathways.Oncotarget 2011; 2:  113 - 121 116 www.impactjournals.com/oncotarget
Interferon/PArAcrIne resPonse
Three classes of IFNs have been identified according 
to the receptor through which they signal. Type I IFNs 
comprise 13 IFN-α subtypes, IFN-β, IFN-κ, IFN-ε, IFN-ο, 
IFN-τ and IFN-δ. All of the type I IFNs signal through 
IFN-AR.  Thus,  mice  deficient  for  IFN-AR  have  an 
increased susceptibility to viral infections [32]. Type II 
IFNs are secreted by lymphocytes in response to different 
pathogens during the adaptive immune response, while 
type III IFNs are not well characterized [33]
Adenovirus-mediated IFN responses are induced, at 
least in part, by the recognition of foreign nucleic acid. 
Unlike  the  inflammatory  responses,  IFN  has  not  been 
shown to be induced during adenoviral interaction with 
cell-surface receptors. Furthermore, the adenovirus-
induced IFN response is cell specific [34]. While myeloid 
dendritic cells (mDCs) recognize adenoviral DNA in the 
cytoplasm, plasmacytoid DCs (pDCs) depend on TLR9, 
located in endosomes.
The discovery of the TLRs resulted in a new and 
focused investigative path for innate immunity [35, 
36]. The mammalian TLR family consists of at least 
11 members localized on the cell surface or inside 
endosomes. Important to adenoviral recognition, TLR9 
localizes  within  endosomes  and  recognizes  adenoviral 
CpG-rich DNA. In response to TLR9-activation, pDCs 
secrete IFN-α via the MyD88-dependent pathway [37]. 
The MyD88-dependent pathway is analogous to the IL-1R 
pathway: after stimulation, MyD88 recruits IL-1 receptor 
associated receptor kinase 1 (IRAK1) and TNF receptor-
associated factor-6 (TRAF6). This complex activates 
MAP kinases and interferon regulatory factor 7 (IRF7). 
In pDCs, this pathway leads to the production of type I 
IFNs [38] (Figure 3), whereas in other types of DCs, such 
as mDCs, it leads to NF-κB activation and subsequent 
increased pro-inflammatory cytokine expression. 
In  mDCs,  macrophages  or  fibroblasts,  IFN 
production is not related to TLR recognition, nor 
dependent  on  the  MyD88/TRIF  pathway  [37].  Rather, 
the presence of a cytosolic receptor, DAI, is activated 
and subsequently induces an IFN response upon foreign 
DNA recognition [21]. The downstream effectors of DAI 
are dependent on TBK1/IKKi and IRF3/7 for type 1 IFN 
induction.  However,  the  recent  generation  of  DAI-KO 
mice has contradicted previous data in the field, which 
demonstrates that DAI expression is not essential for 
the IFN response. Whether the MyD88/TRIF and DAI 
pathways are redundant in some cells, or other receptors 
exist, is currently unknown. 
The  aforementioned  pathways  that  lead  to 
the induction of IFN expression are not affected by 
adenovirus. Some viruses such as hepatitis C virus (HCV) 
or varicella-zoster virus (VZV) have been demonstrated to 
prolong viral replication in tissues by inhibiting type I IFN 
transcription [39, 40]. In contrast, type I IFN expression 
is  not  affected  by  adenoviral  infection.  However,  the 
downstream  pathways  of  IFN  expression  are  blocked. 
Regardless,  once  induced,  IFN  acts  in  a  paracrine/
autocrine fashion to block adenoviral replication.
Type I IFNs bind to their cognate receptor which 
leads  to  the  activation  of  JAK1/TYK2  kinases  and  is 
followed  by  the  recruitment  and  phosphorylation  of 
STATs. STAT1 and STAT2 associate with IRF9 to form 
ISGF3,  which  induces  more  than  300  IFN-stimulated 
genes  (ISGs)  [41].  The  intensity  of  this  response  is 
drastically  reduced  during  adenoviral  infection,  which 
inhibits the formation of ISGF3. As a result, only a few 
ISGs, such as Protein Kinase R (PKR) and Myxovirus 
resistance A protein (MxA) [42] have been shown to be 
activated upon adenoviral infection. PKR belongs to a 
family of protein kinases that respond to environmental 
stresses  by  phosphorylating  E1F2α  to  regulate  protein 
synthesis. At the N-terminus of PKR, two RNA binding 
motifs exist that release the negative steric hindrance and 
allow dimerization of PKR on contact with RNA [43]. In 
contrast, MxA GTPases are involved in vesicle budding, 
organogenesis and cytokinesis. By virtue of their location 
near  the  endoplasmic  reticulum,  MxA  can  block  viral 
replication at early time points by trapping essential viral 
proteins [44]. 
A  complex  interplay  between  the  IFN  and 
inflammatory responses is necessary to clear adenoviral 
infections. In bone marrow-derived macrophages, IRF3   
activation  and  IFN  induction  have  been  shown  to  be 
influenced by inhibitors of the inflammatory pathway, such 
as JNK inhibitors [45]. Interaction of integrins with the 
adenoviral fiber RGD motif induces JNK to prime IRF3, 
whose full activation requires phosphorylation by TBK1. 
In addition, the recruitment of NK cells into the liver 
Figure 3: Interferon induction during adenovirus infection. 
In plasmacytoid DC adenoviral DNA activates TLR9 in plasmacytoid 
DCs, whereas DAI is activated in mDCs. The down-stream signaling 
converges in TBK1/IKKί activation and culminates in IRF3/7 transfer 
to the nucleus to induce IFN transcription.Oncotarget 2011; 2:  113 - 121 117 www.impactjournals.com/oncotarget
after intravenous injection of adenovirus is independent 
of the IFN response. However, the activation of NK cells 
requires IFN downstream signaling, since recruited NK 
cells in IFN-R-/- mice fail to control adenoviral infection 
[46]. 
Through evolution, adenoviruses have developed 
mechanisms to dampen and escape the immune response. 
These are more effective against ISGs than inflammatory 
mediators.  Moreover,  during  adenoviral  infections, 
inflammatory mediator levels such as IL-1α increase 20-
fold, while IFN-α increases less than 2-fold [3]. However, 
genetic manipulation of adenovirus is independent 
of  the  IFN  response.  More  importantly,  generation  of 
adenoviruses  lacking  specific  innate  immune  system-
interfering genes has allowed the mechanistic study and 
determination of relevance for many genes required for 
innate immune system-mediated adenoviral clearance 
[47].
Immune Response to Adenoviral Vectors
Adenoviruses are the most commonly used gene 
therapy vectors. Due to the small size, the adenoviral 
capsid  structure  does  not  allow  for  extra  DNA  to  be 
packaged properly. Thus, in order to insert a gene of 
interest into the adenoviral genome, a similar size of viral 
DNA must be removed. Furthermore, the viral cytopathic 
effect has to be minimized. The first generation E1-deleted 
adenoviral vectors were less cytopathic but induced innate 
immune  responses  very  quickly  [28,  48].  To  decrease 
overall immune activation, vectors were deleted of more 
dispensable transcriptional regions. Three generations of 
vectors were created. Of those, ‘gutless’ vectors, deleted 
for the entire adenoviral genome, had the least antigenic 
and immunostimulatory properties. 
Adenoviral  vectors  deficient  of  early  transcript 
regions showed a different sensitivity towards IFN and 
inflammatory responses. Deletion of the E1 region reduced 
the IFN resistance more than deleting E4. Furthermore, 
vectors  lacking  E3  genes  were  more  vulnerable  to 
inducing the inflammatory response. It should be noted 
that the E2 transcripts have not been shown to block the 
innate immune response. Rather, E2 gene transcripts boost 
the immune response [49].
Deletion of E1A has been shown to be very important 
for inhibiting the immune response. The products of E1A, 
289R  and  243R,  named  after  their  amino  acid  residue 
length, not only bind to cell cycle regulatory proteins such 
as pRB, but also have transcriptional activator/repressor 
properties. It is clear that E1A can rescue other viruses 
from the IFN response by inhibiting the formation of 
the ISGF3 complex [50, 51]. For example, E1A inhibits 
transcription of JAK1 in epithelial cells [42]. In contrast, 
the E1B region encodes three major proteins that are 55-
kDa, 19-kDa and 17-kDa in size. The components of 
E1B, complexed with the E4-ORF6, block host mRNA 
transport and p53 transcriptional activity while facilitating 
late viral mRNA expression. Furthermore, the E1B-19-
kDa component is a BCL2 homologue and acts as a potent 
inhibitor of apoptosis.
Adenoviral transduction of cells results in the 
transcription of both host and viral DNA, resulting in 
a greater amount of total DNA within a cell, which can 
trigger host cell defenses. However, the adenovirus has 
selectively  evolved  to  deal  with  those  cell  defenses. 
E4  proteins  hijack  the  machinery  associated  with  the 
DNA damage pathways [52]. There are six E4 proteins 
produced through differential splicing of the open reading 
frame (ORF). The E4ORF3 and E4ORF6 show functional 
redundancy. Both form complexes with the E1B-55kDa 
component and regulate late adenoviral gene expression.
Inflammatory  responses  induced  by  adenoviral 
transduction are also counteracted by the E3 region 
transcripts. Inserting the E3 region in recombinant 
vectors decreases the maximal innate immune response, 
which consequently permits long term adenoviral gene 
expression [53]. The E3-14.7 kDa component inhibits 
the  NF-κB-induced  transcription  of  inflammatory 
mediator expression [54], while the E3-10.4kDa/14.5kDa 
components  inhibits  TNFα  and  FAS  ligand-induced 
cell death by internalizing receptor internalization and 
degradation alpha/beta (RIDα/β) receptors [55]. The E3-
19kDa glycoprotein inhibits peptide presentation by MHC 
class I via a specific motif at the carboxy terminus, which 
retargets MHC class I to the endoplasmic reticulum [56]. 
The functional relevance of adenoviral protein 
interference  with  innate  immunity  must  be  carefully 
understood if an effective therapy can be produced. For 
gene therapy, which requires the prolonged expression of 
therapeutic genes by a transduced cell, maintenance of cell 
viability and the reduction of inflammation is required. 
The E3-14.7kDa component inhibits the NF-κB-induced 
transcription of inflammatory mediator expression [54], 
while  the  E3-10.4kDa/14.5kDa  component  inhibits 
TNFα  and  FAS  ligand-induced  cell  death  by  receptor 
internalization  and  degradation  of  alpha/beta  (RIDα/β) 
receptors  [55].  In  addition,  inflammation  can  be 
further reduced by immunosuppressive drugs, such as 
cyclophosphamide, which have been shown to enhance 
the effectiveness of adenoviral vectors in different species 
in non-toxic doses [58, 59]. 
The overall intensity of the systemic immune 
response will depend on the level of induced inflammatory 
mediators by the infected cell. Fiber modifications have 
expanded the spectrum of cells that adenoviruses can 
infect, which consequently increases the risk of adverse 
effects, especially when injected systemically. However, 
intravascular delivery of gene vectors is required for 
effectively treating metastatic disease or the transduction 
of large number of cells in vivo.Oncotarget 2011; 2:  113 - 121 118 www.impactjournals.com/oncotarget
Intravascular delivery
Irrespective of the fiber modifications, adenoviruses 
are sequestered by liver cells after intravascular injection 
[60]. When the liver is not the direct target, intravascular 
delivery of naked virus has been associated with adverse 
side-effects and limited efficacy. However, the discovery 
of coagulation factor binding properties of virions and 
differences between adenoviral groups has elucidated the 
mechanism to avoid for liver detargeting [61, 62]. Of the 
different strategies used to limit the toxicity of adenoviral 
vectors during systemic administration, only a handful 
have  been  beneficial  including  surface  modifications, 
genetic deletion and use of cell carriers. 
Surface  modifications  have  been  of  great  interest 
not only for intravascular delivery but also for improving 
cell  transduction  since  wild-type  adenovirus  fibers 
cannot  transduce  target  cells  lacking  CAR.  However, 
fiber modifications alone [24] have not proven to limit 
the binding with coagulation factors, such as FX or FIX. 
Structural  and  mutagenesis  studies  have  shown  Ad5 
hexon hypervariable regions (HVR) 5 and 7 to be critical 
for this interaction [63]. To prevent this interaction, 
genetic  modifications,  hexon  serotype  substitution  and 
PEG-masking are useful approaches with proven success, 
while  maintaining  efficacy.  By  genetically  inserting  a 
large  amino  acid  biotin  acceptor  peptide  (BAP)  into 
HVR5,  affinity  to  FX  factor  was  reduced  10,000-fold. 
This allowed a 10-fold increase in the maximum tolerated 
dose  [64].  Substitution  of Ad5  hexon  with  serotype  3 
had very similar effects [65]. Thus, hexon modifications 
promote immune escape, which is critical to successful 
therapy since most patients already possess circulating 
antibodies to Ad5 hexon [66]. 
Polyethylene  glycol  (PEG)  is  a  linear  synthetic 
polymer that can be synthesized to varying lengths, from 
200-40,000D.  Its  properties  include  low  toxicity,  low 
immunogenicity and hydrophilicity, making it a very 
attractive compound for modifications of various peptides 
or proteins. This has also proven true for adenovirus 
PEGylation  [67].  The  PEG  20kDa  length  has  proven 
to  be  most  effective  [68,  69].  Decreased  activation  of 
the immune response and reduced IL-6 expression was 
inversely  correlated  with  the  PEGylation  rate  when 
compared to native Ad5 [70, 71]. 
Hepatic detargeting can also be achieved using cells 
as vehicles for adenovirus delivery, instead of ‘naked’ 
adenovirus [72]. Our lab has shown that the inflammatory 
response is reduced by using mesenchymal stem cells 
loaded with adenoviruses [73]. These immunosuppressive 
properties can therefore be harnessed to achieve long-
term transgene expression. Also, stem cells loaded with 
adenoviral vectors have shown to be attracted to growth 
factors or chemokines and can target specific niches even 
when injected systemically [74]. 
Our rationale for investigating and exploring the 
adenovirus for gene therapy is to further increase the 
efficacy for potential clinical use in glioblastoma patients. 
One such way to do this is by using a surface modification 
combining  PEGylation  with  liposome  encapsulation  of 
the adenovirus [75]. This has been performed with success 
using systemically-delivered PEGylated adenovirus with 
tumor cell-specific promoters to control metastasis [69]. 
However, as we investigate new mutated or aberrantly 
expressed tumor promoters, more effective adenoviral 
vectors will be constructed. 
conclusIons
The innate immune response to adenoviral vectors 
will  always  interfere  with  gene  therapy  in  some  way. 
During each step of viral delivery there is a barrier to 
overcome.  Many  different  sensors  exist  for  adenoviral 
replication starting from the initial attachment to the cell 
surface via the CAR and integrins, later in endosomes 
via TLRs, in the cytoplasm and even in the nucleus. 
Modifications have made adenoviral vectors even more 
sensitive to innate immune responses. Understanding 
these different pathways and how to modulate them will 
bring us closer to clinical use. Cell specificity appears to 
be a major limitation in predicting human innate immune 
responses. The unpredictable adverse effects encountered 
during intravascular therapy should not make us bitter 
about the potentials of adenoviral vectors. Experience 
with ‘gutless’ vectors has proven that less is more, even 
in medicine. 
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